Literature DB >> 20359626

The epidemiology of myelodysplastic syndromes.

Mikkael A Sekeres1.   

Abstract

The incidence of the myelodysplastic syndromes (MDS) in the United States is reported as 3.4 per 100,000 people, translating to over 10,000 new diagnoses annually. This figure is considered to be an underestimate as our data capture techniques improve, and probably translates to a prevalence of approximately 60,000 people or more living with the disease. Patients are in their seventh or eighth decades at diagnosis, typically present with cytopenias, and have substantive transfusion requirements. The most common risk factors for developing MDS include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to industrial chemicals. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359626     DOI: 10.1016/j.hoc.2010.02.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  37 in total

1.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.

Authors:  Stefani Parmentier; Johannes Schetelig; Kerstin Lorenz; Michael Kramer; Robin Ireland; Ulrich Schuler; Rainer Ordemann; Gabi Rall; Markus Schaich; Martin Bornhäuser; Gerhard Ehninger; Frank Kroschinsky
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

3.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

Review 4.  Are ongoing trials on hematologic malignancies still excluding older subjects?

Authors:  Antonio Cherubini; Francesca Pierri; Beatrice Gasperini; Elisa Zengarini; Annarita Cerenzia; Elisabetta Bonifacio; Flavio Falcinelli; Fabrizia Lattanzio
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

5.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

Review 6.  Genetic predisposition syndromes: when should they be considered in the work-up of MDS?

Authors:  Daria V Babushok; Monica Bessler
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-12       Impact factor: 3.020

7.  Hyperostosis - an unusual radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia.

Authors:  Arie Franco; Kristopher N Lewis; Joshua M Blackmon; Elizabeth J Manaloor
Journal:  J Radiol Case Rep       Date:  2010-11-01

Review 8.  Epidemiology of myelodysplastic syndromes.

Authors:  Xiaomei Ma
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

9.  Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.

Authors:  Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Marialena Trivella; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

10.  Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.

Authors:  Maria Helena Ornellas; Monique De França Silva; Cristiana Solza; Stella Beatriz Sampaio De Lucena Gonçalves; Liliane Silva De Almeida; Jackline De Paula Ayres-Silva; Taís Leite Seixas; Elenice Ferreira Bastos; Thomas Liehr; Gilda Alves
Journal:  Mol Clin Oncol       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.